FDC Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lbierrijyp0hnsv1vv0e74tn.pdf

Key Takeaways


Margin Walk: The Inflation Squeeze and the Price-Hike Antidote

Sanjay Jain: "The exact quantification we will not be able to do as of now, but I can give you a broad guidance on that considering the fact the goods which have been sold in the Q1 are partially from the carry forward of the March quarter inventory and partially from the Q1 inventory. Now whatever inventory which are going to be get sold in the Q2 almost purely of a Q1 inventory means the inventory with the increased sales price. So, with this increase sales price the margins will obviously improve in the Q2 as compared to Q1 margin but having said this we also have to wait and watch any further impact on the raw material and packing material."

Domestic Formulations: Volume Engine, Brand Focus

Mayank Tikkha: "Again, we are planning in nice fashion. We are very aggressive but as I said that all these plans are plans till the times you don't get the execution right and also the results right. But yes, the trends are very encouraging. We have continued good run."

Exports: US-Led Surge, Profit Share Normalizes

Ameya Chandavarkar: "So, yes, from a sales perspective excluding profit share you can use FY21 as a base but what happened in FY21 in terms of profit share was an anomaly. So, that's really why this year we find it very challenging to hit that same profit share number."

Capital Allocation & Investments


Pricing Strategy & NLEM Dynamics


Guidance & Commitments

CommitmentSpecificsTimeline
Price hike visibilityFull impact of 10%+ WPI-linked price hike on scheduled formulations visibleEnd of Q2 FY23
NLEM price hike impactFull impact of 10.7% NLEM increase reflected in financialsQ2 FY23
Gross margin recoveryMargins to improve in Q2 vs. Q1 as goods sold carry increased sales price, subject to no further raw material cost increasesQ2 FY23
Export growthGrowth trajectory expected to continue for the rest of the yearFY23
Geographical revenue disclosureQuarterly breakup of revenues by India, US, other exports, APIStarting from a future quarter
Ophthalmic CAPEX guidanceAsset turn and top-line expectations to be sharedNo date (once available)

Key Metrics

MetricQ1 FY23
Overall revenue growth11% YoY
Domestic formulation growth8% YoY, against a high base of 68% growth in Q1 FY22; real growth excluding COVID products would have been ~15%
Export formulation revenue growth42% YoY (standalone)
API business revenue growth25% YoY (standalone)
Revenue growth break-up11.5% overall, volume growth 7.6%, price growth 2.1%, new product growth 1.8%
EBITDA margin20%, compared to 31% in Q1 FY22
Gross margin impact from raw and packing material~5% of revenue, absolute impact of ₹34 crores
Employee cost~20% of revenue, slightly lower than Q1 FY22
Sales and marketing expenses~8% of revenue, compared to ~6.75% in Q1 FY22
Fair value impact on financial instruments₹15 crores temporary provision, reversed post-quarter with market rebound
PBT₹90 crores, compared to ₹127 crores in Q1 FY22
Domestic formulation sales₹423 crores (out of ₹493 crores total revenue)
NLEM portfolio price increase10.7% taken; NLEM portfolio is ~45% of domestic formulation business
Medical Representative count3,615 as of June, up from ~3,242 in March, addition of ~400 for new Zocon division
Cash on books~₹750 crores
CAPEX planned for ophthalmic line₹70–80 crores at Waluj plant